

Datasheet for 100-401-149**EGFR Antibody****Overview**

Description:	Anti-EGFR (RABBIT) Antibody - 100-401-149
Item No.:	100-401-149
Size:	250 µL
Applications:	IHC, IP, WB
Reactivity:	Human, Rat
Host Species:	Rabbit

Product Details

Background: EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial to maintaining a normal balance in cell growth and development. Growth factor receptors are involved not only in promoting the proliferation of normal cells but also in the aberrant growth of many types of human tumors. For example, the epidermal growth factor receptor (EGFR) is mutated and/or over-expressed in many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. Over-expression of the EGFR gene occurs in carcinomas with and without gene amplification. EGFR and ErbB-2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. EGFR belongs to a family of growth factor receptors, which also includes ErbB-2/HER-2/neu, ErbB-3/HER-3/neu and ErbB-4/HER-4/neu. EGFR can heterodimerize with each of the members of this family.

Synonyms: rabbit anti-EGFR Antibody, rabbit anti-epidermal growth factor receptor antibody, Receptor tyrosine-protein kinase erbB-1 antibody, c-erbB-1 antibody

Host Species: Rabbit

Clonality: Polyclonal

Format: Antiserum

Target Details

Gene Name: EGFR

Reactivity: Human, Rat

Immunogen Type:	Conjugated Peptide
Immunogen:	This whole rabbit serum was prepared by repeated immunizations with a peptide synthesized using conventional technology. The sequence of the epitope maps to a region near the carboxy terminus which is identical in human, mouse and rat EGFR.
Purity/Specificity:	This antiserum is directed against human epidermal growth factor receptor (EGFR) and is useful in determining its presence in western blotting and immunoprecipitation experiments. This antibody can detect EGFR from human, mouse and rat sources. Reactivity of this antibody with EGFR from other species is unknown. No reaction is observed against ErbB-2, ErbB-3 or ErbB-4.
Relevant Links:	<ul style="list-style-type: none">• UniProtKB - P00533• NCBI - 29725609• GeneID - 1956

Application Details

Tested Applications:	IHC, IP, WB
Application Note:	Anti-EGFR antibody has been tested by and is specifically designed for ELISA, immunoblotting, immunoprecipitation, and immunohistochemistry. Reactivity in other assays is likely, but has not been determined. Recognition of EGFR is independent of the phosphorylation status at tyrosine 1173. A431 cells, keratinocytes in normal epidermis, or placenta are typically used as positive control sources. The antigen is typically localized in the cell membrane. For western blotting, good results are also achieved on PVDF membranes blocked with 5% lowfat milk diluted in TTBS for 1 hour at room temperature. Also, dilute the primary antibody and secondary in 5% lowfat milk in TTBS. Anti-EGFR can be diluted up to 1:10,000 for immunoblot depending on the cell line and the amount of EGFR in a particular lysate. For immunoprecipitation, use approximately 10 µl of the antibody. The immunoprecipitation mix should contain the antibody, 25 µl of Protein A-agarose beads and 1.0 ml of lysate (lysate contains approximately 1.0 mg of total protein). This mixture should be rotated overnight at 4°C and then washed 3 times with lysis buffer (used to prepare the lysate). The resulting bead complex is dissolved in 20-30 µl of 3X SDS-PAGE sample buffer and approximately 15 µl is loaded per lane on an 8% polyacrylamide gel.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000 - 1:50,000
IHC:	2.5 µg/mL
IP:	10 µl
WB:	1:1,000 - 1:10,000


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	85 mg/mL by Refractometry
Buffer:	None
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.


Images



Western Blot


Expression of corneal epithelial gene markers. (B) The relative protein expression levels of EGFR (p/n 100-401-149), involucrin and TG1 as determined by Western blot assay; β -actin (p/n 600-401-886) was used as a loading control, and blocking buffer (p/n MB-070).

Fig 3. PMID: 19638217



Immunohistochemistry

Immunohistochemistry of Anti-EGFR Antibody with positive staining.



Western Blot

Combined immunoprecipitation and western blot using anti-EGFR antibody. Lysates were prepared from GN4 rat liver epithelial cells both with (+) EGF treatment for 15' at 100 ng/ml and without (-) the addition of EGF. The combination of immunoprecipitation and western blotting was performed using the anti-EGFR antibody for immunoprecipitation (10 µL) followed by western blot detection using an anti-phosphotyrosine antibody (Panel A). This was repeated in reverse order using a 1:2000 dilution of anti-EGFR for western blot (Panel B). Visualization occurred using an ECL system. Film exposure was approximately 1'. Other detection systems will yield similar results.



Western Blot

Western blot using Rockland's anti-EGFR antibody. Lane 1: unstimulated A431 whole cell lysates (p/n W09-000-361). Lane 2: EGF stimulated A431 whole cell lysates (p/n W09-000-362). Shows detection of a band at ~170 kDa corresponding to human EGFR present in unstimulated and stimulated (50 ng/ml for 15 min) lysates (arrowhead). Loaded: 30 μ g lysate was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. Primary Antibody: Anti-EGFR at 1:1,000 overnight at 4° C. Secondary Antibody: IRDye® 800 conjugated Gt-a-Rabbit IgG (H&L) MX10 (p/n 611-132-122) at 1:10,000 dilution of for 45 min at room temperature (800 nm channel, green). Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red). IRDye® 800 fluorescence image was captured using the Odyssey® Infrared Imaging System developed by LI-COR. IRDye is a trademark of LI-COR, Inc. Other detection systems will yield similar results.

References

- Saheki Y et al. Control of plasma membrane lipid homeostasis by the extended synaptotagmins. *Nat Cell Biol.* (2016)
- Quintero, D et al. EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells. *Biotechnology and Bioengineering* (2016)
- Andersson N et al. Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition. *J Mol Endocrinol.* (2014)
- Khoh-Reiter S et al. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. *BMC Ophthalmol.* (2009)
- Miettinen PJ et al. Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal β -cell growth. *Diabetes.* (2006)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.